DKDominique P.V. de Kleijn

Dominique P.V. de Kleijn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dominique P.V. de Kleijn has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Gerard Pasterkamp

    From the Laboratory of Experimental Cardiology, University Medical Center Utrecht (F.A., M.B.S., L.T., C.T., I.E.H., P.A.D., G.P., D.P.V.d.K.), and Interuniversity Cardiology Institute of the Netherlands (F.A., P.A.D., G.P., D.P.V.d.K.), Utrecht, the Netherlands; School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland (L.A.J.O.); and Opsona Therapeutics Ltd, Trinity Centre for Health Sciences, St James Hospital, Dublin 8, Ireland (B.K., P.M.).

    2 shared publications
  • Andre Boon Hwa Choo

    Biotherapeutics Development, Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (ASTAR), Singapore, Singapore

    1 shared publication
  • Aryan Vink

    From the Experimental Cardiology Laboratory (M.G.I., W.P., G.P., D.P.V.d.K.) and the Departments of Pathology (A.V., P.H.v.d.K.) and Vascular Surgery (F.L.M.), University Medical Center Utrecht; the Department of Immunology (I.E.D., J.D.L.), Erasmus Medical Center Rotterdam; the Interuniversity Cardiology Institute of the Netherlands (ICIN) (W.P., D.P.V.d.K.), Utrecht; and the Department of Vascular Surgery (J.-P.P.M.d.V.), Saint Antonius Hospital, Nieuwegein, the Netherlands

    1 shared publication
  • Brian Keogh

    From the Laboratory of Experimental Cardiology, University Medical Center Utrecht (F.A., M.B.S., L.T., C.T., I.E.H., P.A.D., G.P., D.P.V.d.K.), and Interuniversity Cardiology Institute of the Netherlands (F.A., P.A.D., G.P., D.P.V.d.K.), Utrecht, the Netherlands; School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland (L.A.J.O.); and Opsona Therapeutics Ltd, Trinity Centre for Health Sciences, St James Hospital, Dublin 8, Ireland (B.K., P.M.).

    1 shared publication
  • Chen Tian Sheng

    Institute of Medical Biology, A*STAR, 8A Biomedical Grove, 138648 Singapore

    1 shared publication
  • Chuen Neng Lee

    Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore

    1 shared publication

Latest Publications

  • Open Access

    Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs

    by Tian Sheng Chen, Fatih Arslan, Yijun Yin, Soon Sim Tan, Ruenn Chai Lai, Andre Boon Hwa Choo, Jayanthi Padmanabhan, Chuen Neng Lee, Dominique Pv de Kleijn, Sai Kiang Lim

    Background: Exosomes or secreted bi-lipid vesicles from human ESC-derived mesenchymal stem cells (hESC-MSCs) have been shown to reduce myocardial ischemia/reperfusion injury in animal models. However, as hESC-MSCs are not infinitely expansible, large scale production of these exosomes would require replenishment of hESC-MSC through derivation from hESCs and incur recurring costs for testing and validation of each new batch. Our aim was therefore to investigate if MYC immortalization of hESC-MSC would circumvent this constraint without compromising the production of therapeutically efficacious exosomes. Methods: The hESC-MSCs were transfected by lentivirus carrying a MYC gene. The transformed cells were analyzed for MYC transgene integration, transcript and protein levels, and surface markers, rate of cell cycling, telomerase activity, karyotype, genome-wide gene expression and differentiation potential. The exosomes were isolated by HPLC fractionation and tested in a mouse model of myocardial ischemia/reperfusion injury, and infarct sizes were further assessed by using Evans' blue dye injection and TTC staining. Results: MYC-transformed MSCs largely resembled the parental hESC-MSCs with major differences being reduced plastic adherence, faster growth, failure to senesce, increased MYC protein expression, and loss of in vitro adipogenic potential that technically rendered the transformed cells as non-MSCs. Unexpectedly, exosomes from MYC-transformed MSCs were able to reduce relative infarct size in a mouse model of myocardial ischemia/reperfusion injury indicating that the capacity for producing therapeutic exosomes was preserved. Conclusion: Our results demonstrated that MYC transformation is a practical strategy in ensuring an infinite supply of cells for the production of exosomes in the milligram range as either therapeutic agents or delivery vehicles. In addition, the increased proliferative rate by MYC transformation reduces the time for cell production and thereby reduces production costs.


  • Open Access

    Modulation of TGF-β/BMP-6 expression and increased levels of circulating smooth muscle progenitor cells in a type I diabetes mouse model

    by Peter E Westerweel, Cindy Tj van Velthoven, Tri Q Nguyen, Krista Den Ouden, Dominique Pv de Kleijn, Marie Jose Goumans, Roel Goldschmeding, Marianne C Verhaar

    Background: Diabetic patients experience exaggerated intimal hyperplasia after endovascular procedures. Recently it has been shown that circulating smooth muscle progenitor cells (SPC) contribute to intimal hyperplasia. We hypothesized that SPC differentiation would be increased in diabetes and focused on modulation of TGF-β/BMP-6 signaling as potential underlying mechanism. Methods: We isolated SPC from C57Bl/6 mice with streptozotocin-induced diabetes and controls. SPC differentiation was evaluated by immunofluorescent staining for αSMA and collagen Type I. SPC mRNA expression of TGF-β and BMP-6 was quantified using real-time PCR. Intima formation was assessed in cuffed femoral arteries. Homing of bone marrow derived cells to cuffed arterial segments was evaluated in animals transplanted with bone marrow from GFP-transgenic mice. Results: We observed that SPC differentiation was accelerated and numeric outgrowth increased in diabetic animals (24.6 ± 8.8 vs 8.3 ± 1.9 per HPF after 10 days, p < 0.05). Quantitative real-time PCR showed increased expression of TGF-β and decreased expression of the BMP-6 in diabetic SPC. SPC were MAC-3 positive, indicative of monocytic lineage. Intima formation in cuffed arterial segments was increased in diabetic mice (intima/media ratio 0.68 ± 0.15 vs 0.29 ± 0.06, p < 0.05). In GFP-chimeric mice, bone marrow derived cells were observed in the neointima (4.4 ± 3.3 cells per section) and particularly in the adventitia (43.6 ± 9.3 cells per section). GFP-positive cells were in part MAC-3 positive, but rarely expressed α-SMA. Conclusions: In conclusion, in a diabetic mouse model, SPC levels are increased and SPC TGF-β/BMP-6 expression is modulated. Altered TGF-β/BMP-6 expression is known to regulate smooth muscle cell differentiation and may facilitate SPC differentiation. This may contribute to exaggerated intimal hyperplasia in diabetes as bone marrow derived cells home to sites of neointima formation.


  • Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti–Toll-Like Receptor-2 Antibody

    by Fatih Arslan, Mirjam B. Smeets, Luke A.J. O'Neill, Brian Keogh, Peter McGuirk, Leo Timmers, Claudia Tersteeg, Imo E. Hoefer, Pieter A. Doevendans, Gerard Pasterkamp, et al.

    Background— Reperfusion therapy for myocardial infarction is hampered by detrimental inflammatory responses partly via Toll-like receptor (TLR) activation. Targeting TLR signaling may optimize reperfusion therapy and enhance cell survival and heart function after myocardial infarction. Here, we evaluated the role of TLR2 as a therapeutic target using a novel monoclonal anti-TLR2 antibody. Method and Results— Mice underwent 30 minutes of ischemia followed by reperfusion. Compounds were administered 5 minutes before reperfusion. Cardiac function and dimensions were assessed at baseline and 28 days after infarction with 9.4-T mouse magnetic resonance imaging. Saline and IgG isotype treatment resulted in 34.5±3.3% and 31.4±2.7% infarction, respectively. Bone marrow transplantation experiments between wild-type and TLR2-null mice revealed that final infarct size is determined by circulating TLR2 expression. A single intravenous bolus injection of anti-TLR2 antibody reduced infarct size to 18.9±2.2% ( P =0.001). Compared with saline-treated mice, anti-TLR2–treated mice exhibited less expansive remodeling (end-diastolic volume 68.2±2.5 versus 76.8±3.5 μL; P =0.046) and preserved systolic performance (ejection fraction 51.0±2.1% versus 39.9±2.2%, P =0.009; systolic wall thickening 3.3±6.0% versus 22.0±4.4%, P =0.038). Anti-TLR2 treatment significantly reduced neutrophil, macrophage, and T-lymphocyte infiltration. Furthermore, tumor necrosis factor-α, interleukin-1α, granulocyte macrophage colony-stimulating factor, and interleukin-10 were significantly reduced, as were phosphorylated c-jun N-terminal kinase, phosphorylated p38 mitogen-activated protein kinase, and caspase 3/7 activity levels. Conclusions— Circulating TLR2 expression mediates myocardial ischemia/reperfusion injury. Antagonizing TLR2 just 5 minutes before reperfusion reduces infarct size and preserves cardiac function and geometry. Anti-TLR2 therapy exerts its action by reducing leukocyte influx, cytokine production, and proapoptotic signaling. Hence, monoclonal anti-TLR2 antibody is a potential candidate as an adjunctive for reperfusion therapy in patients with myocardial infarction.


  • High Levels of Myeloid-Related Protein 14 in Human Atherosclerotic Plaques Correlate With the Characteristics of Rupture-Prone Lesions

    by Mihaela G. Ionita, Aryan Vink, I. Esmé Dijke, Jon D. Laman, Wouter Peeters, Petra Homoet van der Kraak, Frans L. Moll, Jean-Paul P.M. de Vries, Gerard Pasterkamp, Dominique P.V. de Kleijn

    Objective— Atherosclerotic plaque rupture can lead to severe complications such as myocardial infarction and stroke. Myeloid related protein (Mrp)-14, Mrp-8, and Mrp-8/14 complex are inflammatory markers associated with myocardial infarction. It is, however, unknown whether Mrps are associated with a rupture-prone plaque phenotype. In this study, we determined the association between Mrp-14, -8, -8/14 plaque levels and plaque characteristics. Methods and Results— In 186 human carotid plaques, levels of Mrp-14, -8, and -8/14 were quantified using ELISA. High levels of Mrp-14 were found in lesions with a large lipid core, high macrophage staining, and low smooth muscle cell and collagen amount. Plaques with high levels of Mrp-14 contained high interleukin (IL)-6, IL-8, matrix metalloprotease (MMP)-8, MMP-9, and low MMP-2 concentrations. Mrp-8 and Mrp-8/14 showed a similar trend. Within plaques, a subset of nonfoam macrophages expressed Mrp-8 and Mrp-14 and the percentage of Mrp-positive macrophages was higher in rupture-prone lesions compared to stable ones. In vitro, this subset of macrophages does not acquire a foamy phenotype when fed oxLDL. Conclusion— Mrp-14 is strongly associated with the histopathologic features and the inflammatory status of rupture-prone atherosclerotic lesions, identifying Mrp-14 as a local marker for these plaques.